The highlight of this meta-analysis was the comprehensive evaluation of the effects of SGLT2 inhibitors on patients with T2DM and NAFLD in terms of blood glucose control, improvement of liver enzymes, and influence on body composition. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.